The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study

Jaewon Lee, MD\(^1\)\(^2\)  
Jin Lim, MD\(^3\)  
Jong Seo Park, MD\(^1\)\(^2\)  
Miso Kim, MD\(^3\)  
Tae-Yong Kim, MD\(^3\)  
Tae Min Kim, MD, PhD\(^3\)  
Kyung-Hun Lee, MD\(^3\)  
Bhumsuk Keam, MD, PhD\(^3\)  
Sae-Won Han, MD, PhD\(^3\)  
Je-Ho Mun, MD, PhD\(^1\)\(^2\)  
Kwang Hyun Cho, MD, PhD\(^1\)\(^2\)  
Seong Jin Jo, MD, PhD\(^1\)\(^2\)

\(^1\)Department of Dermatology, Seoul National University Hospital, Seoul, \(^2\)Center for Skin Cancer and Adverse Skin Reaction to Chemotherapeutics, Seoul National University Cancer Hospital, Seoul, \(^3\)Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

Purpose  
Patients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.

Materials and Methods  
In this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.

Results  
Of 375 evaluated subjects with anticancer therapy, 136 (36.27\%) and 114 (30.40\%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungal inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungal inflammation and palmoplantar lesions scored the highest DLQI.

Conclusion  
We believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.

Key words  
Adverse drug reaction, Antineoplastic agents, Quality of life, Dermatology Life Quality Index

Introduction  
Patients with cancer undergoing treatment with anticancer agents often experience various skin problems, such as pruritus, dry skin, facial papulopustules, paronychia, etc. They are at high risk of skin problems, because anticancer agents affect not only cancer cells, but also rapidly proliferating skin cells [1-4]. To date, significant progress has been made in the development of anticancer agents. A number of new anticancer agents, including targeted agents, have been developed and are widely used nowadays. Accordingly, new
agent-related skin problems, such as facial papulopustules and hand-foot reaction induced by various tyrosine kinase inhibitors, also became prevalent [2-10].

Despite their high prevalence, the skin problems due to anticancer therapy are often neglected because clinicians and healthcare providers are usually more focused on clinical response of tumor itself or potentially life-threatening side effects such as neutropenia. However, adverse skin reactions to these therapies are sometimes so severe that they make significant disturbance to patients and the dose of anticancer agent should be adjusted at times, meaning that they can affect not only the patients’ quality of life (QoL), but also optimal anticancer treatment. Therefore, they must not be ignored and should be evaluated thoroughly by managing physicians.

In this study, we aimed to evaluate the impact of anticancer agents on patients’ QoL. The patients under active anticancer therapy were surveyed using the Dermatologic Life Quality Index (DLQI), a useful dermatology-specific health-related QoL questionnaire. DLQI score was analyzed according to various clinical factors, including demographics, anti-cancer therapy, and specific skin problems induced by anticancer agents.

Materials and Methods

1. Study design

We conducted a cross-sectional study using a questionnaire survey and their medical records review. Subjects suffering from cancer were recruited from the Seoul National University Cancer Hospital between February 2016 and April 2016. They were adult patients treated actively with anticancer agents at the time of the study; therefore, patients with only past history of anticancer therapy were excluded. Clinical information was obtained from both the review of medical records and questionnaires.

2. Review of medical records

The following clinical information was obtained for each subject from retrospective review of electronic medical records: (1) demographic data (sex, age); (2) type of cancer (cancer of the liver, thyroid, oral cavity, musculoskeletal, central nervous system, biliary ducts, colorectum, head and neck, bladder, kidney, stomach, breast, uterine cervix, prostate gland, pancreas, lung, skin, and hematologic malignancies); (3) type of anticancer agents: targeted agents (trastuzumab, cetuximab, imatinib, bevacizumab, erlotinib, gefitinib, sunitinib, crizotinib, sorafenib, rituximab, pertuzumab, and ramucirumab) and non-targeted chemotherapeutic agents (docetaxel, paclitaxel, cyclophosphamide, adriamycin, vincristine, 5-fluouracil, cisplatin, oxaliplatin, carboplatin, etoposide, gemcitabine, capecitabine, irinotecan, navelbine, and pemetrexed); (4) the duration of current anticancer therapy; and (5) radiation therapy history.

3. Contents of the questionnaire

Using the questionnaire, subjects were asked if they underwent anticancer therapy at the time of the study and if they suffered from the following skin problems: (1) hair loss; (2) itching; (3) dry skin; (4) easy bruising; (5) pigmentation of lips and mucosae; (6) papulopustules on face, scalp, chest, and back; (7) periungual inflammation; (8) nail changes in color or shape; and (9) palmoplantar lesions with redness, exfoliation, and pain. The impact of skin problems on their QoL was evaluated using DLQI (Dermatology Life Quality Index, AY Finlay, GK Khan, April 1992; all rights reserved; License ID of this study: CUQoL1166), which includes questions about how much skin problems affect patients’ QoL during a past week (symptoms like itching, pricking, or pain, shamefulness, disturbances in performing routine tasks, changes in the selection of clothes, impact on social activities or leisure, difficulties in physical, academic or occupational activities, relationship with other people, and sexual life, and distraction they had due to the treatment). A higher DLQI score means a greater impairment of QoL.

4. Statistical analysis

IBM SPSS statistics ver. 21.0 (IBM Corp., Armonk, NY) was used for statistical analysis. The differences of DLQI score associated with demographic factors (sex and age), the type of anticancer agents, radiation therapy history, and the type of skin problems were considered statistically significant if the p-values < 0.05 using Student’s t test. Jonckheere-Terpstra test was performed to find a correlation between the duration of anticancer therapy and DLQI scores.

5. Ethical statement

The study protocol was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 1601-058-734), and written informed consent was obtained from all subjects.
Table 1. Clinical characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Cancer type</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Breast cancer</td>
<td>Colorectal cancer</td>
<td>Others</td>
<td></td>
</tr>
<tr>
<td>No. of subjects</td>
<td>375</td>
<td>136</td>
<td>114</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>155 (41.3)</td>
<td>0</td>
<td>63 (55.3)</td>
<td>92 (73.6)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>220 (58.7)</td>
<td>136 (100)</td>
<td>51 (44.7)</td>
<td>33 (26.4)</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>223 (59.5)</td>
<td>119 (87.5)</td>
<td>54 (47.4)</td>
<td>50 (40.0)</td>
<td></td>
</tr>
<tr>
<td>≥ 60</td>
<td>152 (40.5)</td>
<td>17 (12.5)</td>
<td>60 (52.6)</td>
<td>75 (60.0)</td>
<td></td>
</tr>
<tr>
<td>Current chemotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-targeted agents only</td>
<td>267 (71.2)</td>
<td>103 (75.7)</td>
<td>74 (64.9)</td>
<td>90 (72.0)</td>
<td></td>
</tr>
<tr>
<td>Any targeted agents</td>
<td>108 (28.8)</td>
<td>33 (24.3)</td>
<td>40 (35.1)</td>
<td>35 (28.0)</td>
<td></td>
</tr>
<tr>
<td>Duration of current chemotheraphy (wk)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 12</td>
<td>137 (36.5)</td>
<td>41 (30.2)</td>
<td>46 (40.4)</td>
<td>50 (40.0)</td>
<td></td>
</tr>
<tr>
<td>13-24</td>
<td>109 (29.1)</td>
<td>51 (37.5)</td>
<td>30 (26.3)</td>
<td>28 (22.4)</td>
<td></td>
</tr>
<tr>
<td>≥ 25</td>
<td>129 (34.4)</td>
<td>44 (32.3)</td>
<td>38 (33.3)</td>
<td>47 (37.6)</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy history</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>97 (25.9)</td>
<td>37 (27.2)</td>
<td>20 (17.5)</td>
<td>40 (32.0)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>278 (74.1)</td>
<td>99 (72.8)</td>
<td>94 (82.5)</td>
<td>85 (68.0)</td>
<td></td>
</tr>
<tr>
<td>Presence of skin problems</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hair loss</td>
<td>283 (75.5)</td>
<td>125 (91.9)</td>
<td>77 (67.5)</td>
<td>81 (64.8)</td>
<td></td>
</tr>
<tr>
<td>Itching</td>
<td>143 (38.1)</td>
<td>61 (44.9)</td>
<td>35 (30.7)</td>
<td>47 (37.6)</td>
<td></td>
</tr>
<tr>
<td>Dry skin</td>
<td>230 (61.4)</td>
<td>99 (72.8)</td>
<td>66 (57.9)</td>
<td>65 (52.0)</td>
<td></td>
</tr>
<tr>
<td>Easy bruising</td>
<td>113 (30.1)</td>
<td>49 (36.0)</td>
<td>31 (27.2)</td>
<td>33 (26.4)</td>
<td></td>
</tr>
<tr>
<td>Pigmentation of lips and oral mucosa</td>
<td>108 (28.8)</td>
<td>37 (27.2)</td>
<td>45 (39.5)</td>
<td>26 (20.8)</td>
<td></td>
</tr>
<tr>
<td>Papulopustules on face, scalp, or trunk</td>
<td>89 (23.7)</td>
<td>40 (29.4)</td>
<td>21 (18.4)</td>
<td>28 (22.4)</td>
<td></td>
</tr>
<tr>
<td>Periungual inflammation with pain</td>
<td>88 (23.5)</td>
<td>42 (30.9)</td>
<td>21 (18.4)</td>
<td>25 (20.0)</td>
<td></td>
</tr>
<tr>
<td>Changes in nail color and shape</td>
<td>196 (52.3)</td>
<td>102 (75.0)</td>
<td>49 (43.0)</td>
<td>45 (36.0)</td>
<td></td>
</tr>
<tr>
<td>Redness, exfoliation, or pain in palms and soles</td>
<td>121 (32.3)</td>
<td>46 (33.8)</td>
<td>38 (33.3)</td>
<td>37 (29.6)</td>
<td></td>
</tr>
</tbody>
</table>

Values are presented as number (%).

Results

1. Demographic and clinical characteristics of study population

A total of 380 patients visiting Seoul National University Cancer Hospital agreed to participate in this study. We excluded five subjects who were not treated with anticancer therapy at the time of the survey, and 375 subjects with anticancer therapy were finally enrolled, including 155 (41.3%) men and 220 (58.7%) women. The mean age was 56.35 years (range 25 to 84 years). The most patients had breast cancer (136, 36.3%), followed by patients with colorectal cancer (n=114, 30.4%), gastric cancer (n=33, 8.8%), lung cancer (n=21, 5.6%), and hematologic malignancy (n=18, 4.8%). Among them, 267 subjects (71.2%) underwent treatment with non-targeted agents, while other 108 subjects (28.8%) were on at least one targeted agent. We looked up specific types of chemotherapeutic agents used in two major cancer groups. First, among the patients with breast cancer, 71 patients were treated with cyclophosphamide, 65 were treated with doxorubicin, 51 with docetaxel, 24 with trastuzumab, 19 with paclitaxel, 11 with pertuzumab, nine with capecitabine, and eight with gemcitabine (counts are redundant because most of the patients were treated with more than one agent, e.g., combination regimen with doxorubicin and cyclophosphamide). Second, among the patients with colorectal cancer, 82 patients were treated with 5-fluorouracil, 65 with oxaliplatin, 34 with irinotecan, 28 with capecitabine, 27 with bevacizumab, and nine with cetuximab (counts are also redundant due to combination regimen such as ‘FOLFOX’). Three hundred and fifty patients (93.3%) complained at least more than one skin problem. All demographic and clinical variables and subgroup description of patients according to cancer type are summarized in Table 1.
Table 2. Dermatologic Life Quality Index scores according to clinical characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Cancer type</th>
<th>Other cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DLQI p-value</td>
<td>Breast cancer DLQI p-value</td>
<td>Colorectal cancer DLQI p-value</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>2.94±0.36</td>
<td>3.43±0.54</td>
<td>2.61±1.49</td>
</tr>
<tr>
<td>Female</td>
<td>4.42±0.40</td>
<td>5.16±0.54</td>
<td>3.25±0.68</td>
</tr>
<tr>
<td><strong>Age (yr)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>4.01±0.37</td>
<td>5.13±0.57</td>
<td>2.37±0.43</td>
</tr>
<tr>
<td>≥ 60</td>
<td>3.51±0.42</td>
<td>5.41±1.56</td>
<td>4.23±0.69</td>
</tr>
<tr>
<td><strong>Current chemotherapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-targeted agents only</td>
<td>3.45±0.33</td>
<td>4.72±0.61</td>
<td>2.86±0.53</td>
</tr>
<tr>
<td>Any targeted agents</td>
<td>4.69±0.54</td>
<td>6.55±1.14</td>
<td>4.25±0.70</td>
</tr>
<tr>
<td><strong>Duration of current chemotherapy (wk)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 12</td>
<td>3.01±0.42</td>
<td>3.54±0.77</td>
<td>2.54±0.61</td>
</tr>
<tr>
<td>13-24</td>
<td>4.15±0.52</td>
<td>4.71±0.75</td>
<td>3.67±0.94</td>
</tr>
<tr>
<td>≥ 25</td>
<td>4.36±0.52</td>
<td>7.20±1.17</td>
<td>4.08±0.73</td>
</tr>
<tr>
<td><strong>Radiotherapy history</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4.74±0.71</td>
<td>7.95±1.36</td>
<td>2.50±1.11</td>
</tr>
<tr>
<td>No</td>
<td>3.48±0.28</td>
<td>4.12±0.50</td>
<td>3.53±0.46</td>
</tr>
</tbody>
</table>

Values are presented as mean±standard error. DLQI, Dermatologic Life Quality Index. *Jonckheere-Terpstra test was performed to find the correlation between the duration of anticancer therapy and DLQI scores. Student’s t-test was performed for other variables.

2. Assessment of DLQI scores according to demographic and clinical factors

Mean DLQI score of total study population is 3.74±0.27 (mean±standard error). DLQI scores according to various clinical factors are presented in Table 2. Female subjects presented higher DLQI scores (mean±standard error, 4.42±0.40) than males (2.94±0.36). Patients on targeted therapies had significantly higher DLQI scores (4.69±0.54) than patients on non-targeted therapies (3.45±0.33). In addition, Jonckheere-Terpstra test revealed more distraction if anticancer treatment was administered for a longer period (J-T value=+2.35; p=0.019). However, DLQI score was not significantly associated with age or the history of radiation therapy. There were differences in DLQI scores between patients with different types of cancer. The patients with breast cancer complained more of skin-related distraction in their daily life (5.16±0.54) than those with colorectal (3.35±0.42) and gastric cancers (2.70±0.87), as shown in Fig. 1.

We did additional sub-analysis according to the specific questions of DLQI. Among the 10 questions of DLQI, breast cancer patients reported higher scores with statistical significance than the other types of cancer in 9 out of 10 questions. Question number 7 (‘Over the last week, has your skin prevented you from working or studying?’) was the only one with no significant difference between the type of cancer (data not shown).

In a subgroup analysis according to the type of cancer, except for patients with breast cancer, sex differences in QoL were not observed in patients with different types of cancer. In colorectal cancer group, patients aged 60 years or older had more distraction than those aged younger than 60 years. Moreover, patients with a history of radiation therapy in breast cancer groups were found to have more dermatology-related distraction in daily life (Table 2).

3. Assessment of DLQI scores according to the skin problems induced by anticancer therapy

Hair loss was the most frequently reported problem, followed by dry skin and changes in nail color or shape (Table 1). We found similar patterns in the subgroup analysis by cancer types. We compared the DLQI scores between the subjects with and without a specific skin problem and found that all investigated skin problems, except hair loss, were associated with significantly higher DLQI scores (Fig. 2). The patients with periungual inflammation presented the highest DLQI score (7.43±0.65), followed by those with palmoplantar...
lesions (6.78±0.61), and papulopustules (6.64±0.72). Similar patterns were also found in the subgroup analysis by the type of diagnosed cancer (S1 Table).

**Discussion**

Despite the growing interest and attention on anticancer therapy-induced skin problems, their impact on QoL distraction was not much considered. In particular, clinical factors
that cause more distraction in dermatology-related QoL have
not been studied, although this information can help clini-
cians to counsel patients and manage their skin problems
during anticancer therapy [11-15]. This study demonstrated
that dermatology-related QoL of the patients undergoing
anticancer therapy was more distracted in women, in
patients with longer duration of anticancer therapy, and in
those with breast cancer.

In this study, we used DLQI to evaluate the dermatology-
related QoL during anticancer therapy. What clinicians see
is sometimes in disagreement with what patients actually
feel, especially in terms of the impact on QoL [1,11,16]. There-
fore, patient-assessed tools that show the effect of the prob-
lem on their QoL are useful in the evaluation. DLQI is the
first dermatology-specific health-related QoL questionnaire,
and its validity and reliability have been tested for over 20
years in various skin diseases. It is a simple, practical,
patient-assessed questionnaire technique evaluating the
impact of many skin diseases and their treatment on patients’
QoL [17-20].

Several studies reported that older patients with skin dis-
orders presented higher DLQI scores than younger ones
[21,22]. However, unlike our first expectations, age did not
affect dermatology-specific QoL of the patients in this study,
except for the patients with colorectal cancer. This finding
suggests that the effect of anticancer therapy on the skin is
not much affected with age.

Instead, women presented higher DLQI than men in this
study. It is frequently seen that women report higher rates
of morbidity and distraction in many diseases [23,24]. This
fact can be explained by the influence of sex-specific differ-
ences on patients’ perception of symptoms. According to
Holm et al. [25], self-reported morbidity is more consistent
with the disease severity among women than men with
atopic dermatitis. This means that men are less likely to com-
plain of their symptoms although their condition is more
severe than in women.

However, considering that the subjects with breast cancer
presented higher DLQI and that the difference of DLQI
between men and women was not found in colorectal and
other cancers, the higher DLQI score in women found in this
study might be related to the fact that more than half of the
women were patients with breast cancer. Although patients
with breast cancer were significantly younger than other
patients, a subgroup analysis in them suggested that the age
was not a causative factor of high DLQI score. Unlike other
patients with cancer, patients with breast cancer showed a
significant difference in the DLQI score between those with
and without radiotherapy history.

Another hypothesis explaining higher DLQI scores in
breast cancer group in this study is that the differences in the
type of chemotherapeutic agents between cancer groups may
have had an effect on the difference in DLQI scores. In breast
cancer group, the majority of patients were treated with tax-
anes (docetaxel, paclitaxel) or anthracyclines (doxorubicin),
which was a unique pattern comparing with other cancer
groups. They have been well known to induce nail and peri-
ungual problems [26,27], that can explain higher DLQI scores
in breast cancer because the patients with periungual inflam-
mation presented higher DLQI scores than ones with any
other skin problems. Even though direct comparison is
impossible because most of the patients were treated with
multiple agent regimen so that the effect of the agents may
have been mixed, it can be one good hypothesis for that.

Recently, targeted agents, including epidermal growth fac-
tor receptor inhibitors became widely used, and some inves-
tigators studied their impact on dermatology-specific QoL.
Rosen et al. [14] previously found more distractions in QoL
in patients treated with targeted therapy than in patients
with non-targeted therapy with regards to total Skinindex-16
scores evaluated in 283 patients with cancer. On the contrary,
Unger et al. [12] showed no significant difference in QoL
between targeted-agents-only group and patients who was
treated with both targeted and classical chemotherapeutic
agents. The discrepancy may result from the differences in
study designs. Rosen et al. [14] enrolled patients in a derma-
tology referral clinic; therefore, there is a possibility that
more severe cases were included in the study. Unger et al.
[12] compared patients with colorectal cancer treated with
cetuximab only and those treated with a combination of
cetuximab and nontargeted agents. In our study, we inclu-
ded patients who underwent anticancer therapy regardless
of referral to dermatologic office, in order to represent better
the population composed of the patients with various degree
of severity in skin problems. In concordance with Rosen et
al. [14], we found that patients on targeted therapy had sig-
nificantly more distraction in QoL than those on non-tar-
geted therapy. Additionally, we found that the top three skin
problems with the highest DLQI scores were periungual
inflammation and papulopustules, which are frequently
observed in patients treated with targeted agents [7-11,28].
Further studies are needed to confirm this finding.

In the comparison between the patients with and without
a specific skin problem, we found no significant difference
between the patients with and without hair loss induced by
anticancer therapy. Although hair loss has been well-known
to negatively impact the QoL in patients with alopecia areata
[29] and patterned hair loss [30,31], our study suggested that
hair loss induced by anticancer therapy did not cause addi-
tional distress in dermatology-specific QoL. Perhaps the dis-
figuration itself had little effect on the QoL distraction in
patients treated with anticancer therapy if it was not associ-
ated with discomfort, such as itching or pain. In addition,
patients expected the development of hair loss during anti-
cancer therapy and took it for granted, whereas they did not expect other skin problems to be induced by anticancer therapy because hair loss is one of the best-known adverse reactions of anticancer therapy.

Interestingly, periungual inflammation and palmoplantar lesion were the top two skin problems with the highest DLQI. They are usually accompanied by pain, and limitation of instrumental and self-care daily activities which makes them distinguishable from other problems [32,33]. These findings suggest that pain is the most important factor that has negative effect on patients’ QoL.

The limitation of this study is that there is a disproportion of clinical characteristics of the study population. Breast cancer and colorectal cancer together affected over 60% of the patients. This may have caused the disproportion of other factors, such as sex and anticancer therapy regimens consequently.

In conclusion, this study showed that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific QoL distraction. All investigated skin problems, except hair loss, significantly impacted dermatology-specific QoL, and periungual inflammation and palmoplantar lesions scored the highest DLQI. Our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

References


